Oligonucleotide Therapeutics Market

Global Oligonucleotide Therapeutics Market: Overview

Oligonucleotides refer to short chain DNA or RNA that are generally made by using automated synthesizers. In addition, purification of oligonucleotide is accomplished by anion exchange chromatography and it is followed by the techniques of freezing and desalting. In addition, synthesis of siRNA duplex oligonucleotide is done through an annealing step in which two purified strands of oligonucleotide are brought closer together in an equimolar ratio.  There exists much difference between oligonucleotide therapeutics and conventional medicine. The oligonucleotide therapeutics are capable of holding back the expression of specific genes. This factor results in the development of brand new oligonucleotides targeting certain genes and treating chronic diseases. Chemically modified artificial nucleic acids are utilized so as to develop these new oligonucleotide therapeutics. The developed artificial oligonucleotides come with better enhanced affinity and in-vivo stability to target mRNA. These factors are likely to act as growth factors for the global oligonucleotide therapeutics market.

Technology, application, and region are the three important parameters based on which the global oligonucleotide therapeutics market has been classified.

Global Oligonucleotide Therapeutics Market: Notable Developments

The global oligonucleotide therapeutics market is marked with presence of quite a few prominent players, thereby making it a fairly competitive market for both the existing players and new entrants. These companies are forging, partnerships, collaborations, and mergers in an effort to gain larger revenue and market share. The following development is expected to play an important role in the market:

• In Dec 2016, US-based Biogen LLC obtained nod from US Food and Drug Administration (FDA) for nusinersen’s new drug application. This new application involves use of Spinraza (nusinersen) injection for the purpose of treating  spinal muscular atrophy in adult and pediatric patients. In this process, a first of its kind antisense oligonucleotides molecule is used for treating spinal muscular atrophy.

Some of the prominent organizations in the global oligonucleotide therapeutics market comprise the below-mentioned:

• miRagen Therapeutics, Inc.
• Ionis Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Biogen Inc.
• Regulus Therapeutics Inc.

Global Oligonucleotide Therapeutics Market: Key Trends

The global oligonucleotide therapeutics market is characterized by the presence of the following restraints, drivers, and opportunities.

Increased Research and Development Activities in the Field to Shoot Up Demand

The growth of the global oligonucleotide therapeutics market is likely to be driven by several factors. The demand for oligonucleotide therapeutics is likely to rise due to the presence of very few approved molecules. This factor offers a plethora of opportunities to the players in the global oligonucleotide therapeutics market for the development of new molecular entities. In addition, the technological upgradation and advancement of chemically synthesized oligonucleotides have resulted in the coming up of more extended and stable half-life molecules. There exists nearly 135 oligonucleotide therapeutics that are in various phases of development of drugs. This new products are likely to make addition to the already existing approved therapeutics that are available in the market today.

Global Oligonucleotide Therapeutics Market: Geographical Analysis

North America is likely to emerge as leading regional force in the global oligonucleotide therapeutics market throughout the tenure of assessment. Presence of several market leaders in the region is one of the major factors contributing toward the growth of the North America market. In addition, commercialization of new molecules and consolidation of market is likely to play important role for the development of the regional market in the years to come.